Takasugi B J, Perry D J, Wheeler R H, Forastiere A A
Am J Clin Oncol. 1986 Aug;9(4):299-301. doi: 10.1097/00000421-198608000-00004.
Thirty-one patients with unresectable squamous cell carcinoma of the head and neck, 28 with local or distant recurrences following primary surgery and/or radiation and three with distant metastases at diagnosis, were treated with cisplatin and methylglyoxal bis-guanylhydrazone (MGBG). Cisplatin was given at 60 mg/m2 i.v. every 21 days X 3, followed by 80 mg/m2 every 28 days in responding patients. MGBG 500 mg/m2 i.v. was given weekly X 5, then every 14 days. Each dose of MGBG was to be escalated in the absence of toxicity, but in the majority of patients doses greater than 500 mg/m2 resulted in unacceptable toxicity. Gastrointestinal symptoms were the major side effects of this combined treatment. In 28 evaluable patients there were two complete remissions and nine partial remissions. This 39% response rate is not different from that reported with either drug alone. Combined cisplatin and MGBG as administered in this study had no apparent advantage compared to either agent alone in this group of patients.
31例不可切除的头颈部鳞状细胞癌患者，其中28例为初次手术和/或放疗后出现局部或远处复发，3例在诊断时即有远处转移，接受了顺铂和丙酮醛双缩氨基脲（MGBG）治疗。顺铂以60mg/m²静脉注射，每21天一次，共3次，随后对有反应的患者每28天给予80mg/m²。MGBG 500mg/m²静脉注射，每周一次，共5次，然后每14天一次。在无毒性的情况下，MGBG的每次剂量可增加，但大多数患者剂量大于500mg/m²会导致无法接受的毒性。胃肠道症状是这种联合治疗的主要副作用。在28例可评估的患者中，有2例完全缓解，9例部分缓解。39%的缓解率与单独使用任何一种药物所报告的缓解率没有差异。在本研究中给予的顺铂和MGBG联合治疗与单独使用任何一种药物相比，在这组患者中没有明显优势。
